Rapid detection and identification of pathogens is crucial to combat biothreat agents. Here, we take a look at some of the emerging technologies and how they could be used to diagnose disease for civilian biodefense.
We take a look at the key microbiome therapeutics currently in the clinical pipeline for recurrent C. difficile infections and their prospects for the treatment of this disease in the future.
In the era of meta-omics, infection control and prevention must consider healthcare-associated infections in the global context of pathobiome.
In a recent study published in Nature Communications, researchers validated a novel screening approach to identify host-directed compounds that reduce the replication of intracellular pathogens, Julie Kaiser explains.
Biothreats are in the limelight of the current military, scientific and medical debate. Although it is arguable whether they are a major impending risk, their political and societal relevance is out of discussion. They are one of the collective fears which characterize our epoch.
Microbial domain biological resource centers that provide researchers with access to living cultures of microorganisms have adopted a code of conduct and best practice to prevent the misappropriation and misuse of microorganisms.
In a recent study published in Nature Communications, researchers demonstrated that acquired resistance to the polymixin antibiotic, colistin, can be detrimental to bacterial survival, revealing unique evolutionary trade-offs of this new form of resistance.
To round up 2017, we asked our Expert panel to choose their top papers from the year. Here, you can discover these articles and the reasons why they were chosen.
Researchers have demonstrated that antibiotic-resistance plasmids persist in the absence of antibiotics, provided that the efficiency of plasmid transfer exceeds a critical threshold, highlighting the limitations of ‘resistance-reversal’ strategies.